PE20201282A1 - Derivados de piridinona y su uso como inhibidores selectivos de alk-2 - Google Patents

Derivados de piridinona y su uso como inhibidores selectivos de alk-2

Info

Publication number
PE20201282A1
PE20201282A1 PE2020000516A PE2020000516A PE20201282A1 PE 20201282 A1 PE20201282 A1 PE 20201282A1 PE 2020000516 A PE2020000516 A PE 2020000516A PE 2020000516 A PE2020000516 A PE 2020000516A PE 20201282 A1 PE20201282 A1 PE 20201282A1
Authority
PE
Peru
Prior art keywords
alk
compound
6alkyl
selective inhibitors
inhibitors
Prior art date
Application number
PE2020000516A
Other languages
English (en)
Inventor
Luca Arista
Sylvie Chamoin
Pier Luca D'ALESSANDRO
Mika Lindvall
Nikolaus Johannes Stiefl
Sylvie Teixeira-Fouchard
Thomas Ullrich
Sven Weiler
Dimitrios Lizos
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20201282A1 publication Critical patent/PE20201282A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referido a un compuesto de formula I, o una de sus sales farmaceuticamente aceptable, en donde A representa a A.1 o A.2; R1 es H, C1-4alquilo o C1-4alcoxi; R2 y R3 es independientemente H, C1-6alquilo, C1-6haloalquilo, entre otros; X es N o -CH; R4 es H, o amino; Y es N o -CR5; R5 es H o F; Z es N o -CR9; n es 0, 1 o 2; W es -C(=O)- o -S(O)2-; R6 y R7 son independientemente H, F, o C1-4 alquilo; R8 es H, C1-6alquilo, C3-6cicloalquiloC1-6alquilo, entre otros. Un compuesto preferido es 5-(5-(1-isopropil-6-oxo-1,6-dihidropiridin-3-il)piridin-3-il)-1-metilindolin-2-ona. Estos compuestos son inhibidores selectivos de alk-2. como inhibidores selectivos de alk-2Tambien se refiere a una composicion farmaceutica que comprende una cantidad terapeuticamente eficaz de dicho compuesto, fabricacion de un medicamento que comprende dicho compuesto y su uso en el tratamiento de anemia cronica, osificacion heterotopica, entre otros.
PE2020000516A 2017-11-24 2017-11-24 Derivados de piridinona y su uso como inhibidores selectivos de alk-2 PE20201282A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2017/057389 WO2019102256A1 (en) 2017-11-24 2017-11-24 Pyridinone derivatives and their use as selective alk-2 inhibitors

Publications (1)

Publication Number Publication Date
PE20201282A1 true PE20201282A1 (es) 2020-11-24

Family

ID=60702886

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000516A PE20201282A1 (es) 2017-11-24 2017-11-24 Derivados de piridinona y su uso como inhibidores selectivos de alk-2

Country Status (24)

Country Link
US (1) US11160797B2 (es)
EP (1) EP3713927B1 (es)
JP (1) JP7091455B2 (es)
KR (1) KR20200091422A (es)
CN (1) CN111433195B (es)
AU (1) AU2017440306B2 (es)
BR (1) BR112020010171A2 (es)
CA (1) CA3081651A1 (es)
CL (1) CL2020001277A1 (es)
CO (1) CO2020005885A2 (es)
CR (1) CR20200211A (es)
CU (1) CU20200035A7 (es)
DO (1) DOP2020000088A (es)
EA (1) EA202091293A1 (es)
EC (1) ECSP20026023A (es)
ES (1) ES2908252T3 (es)
IL (1) IL274722A (es)
JO (1) JOP20200127A1 (es)
MX (1) MX2020005405A (es)
PE (1) PE20201282A1 (es)
PH (1) PH12020550763A1 (es)
RU (1) RU2020120538A (es)
SG (1) SG11202003920QA (es)
WO (1) WO2019102256A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021222875A1 (en) * 2020-04-30 2021-11-04 Keros Therapeutics, Inc. Methods of using alk2 inhibitors
CN113354631B (zh) * 2021-06-01 2022-11-18 江苏大学 一种1,3,4-噁二唑衍生物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ257631A (en) 1992-11-17 1996-03-26 Ludwig Inst Cancer Res Serine/threonine kinase domain-containing protein, dna and hosts therefor
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US8895711B2 (en) 2006-04-18 2014-11-25 The Trustees Of The University Of Pennsylvania Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)
MX2009002418A (es) 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
EP2270229A1 (en) 2006-09-12 2011-01-05 The General Hospital Corporation Inhibitors of bone morphogenetic protein (BMP) signalling for therapeutical purposes
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
AU2011249912A1 (en) * 2010-05-07 2012-11-29 Genentech, Inc. Pyridone and aza-pyridone compounds and methods of use
EP2949338B1 (en) 2010-08-20 2017-10-25 Wyeth LLC Designer osteogenic proteins
JP2014504286A (ja) 2010-12-06 2014-02-20 ピラマル エンタープライジーズ リミテッド 置換イミダゾキノリン誘導体
AR090220A1 (es) 2012-03-01 2014-10-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
EP3122355A4 (en) * 2014-03-26 2017-08-09 The Brigham and Women's Hospital, Inc. Compositions and methods for inhibiting bmp
WO2016054406A1 (en) * 2014-10-01 2016-04-07 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
ES2766835T3 (es) * 2015-04-16 2020-06-15 Merck Patent Gmbh Derivados de 3-(1H-bencimidazol-2-il)-1H-piridin-2-ona

Also Published As

Publication number Publication date
WO2019102256A1 (en) 2019-05-31
US11160797B2 (en) 2021-11-02
US20200360357A1 (en) 2020-11-19
SG11202003920QA (en) 2020-06-29
ES2908252T3 (es) 2022-04-28
JP7091455B2 (ja) 2022-06-27
MX2020005405A (es) 2020-08-13
DOP2020000088A (es) 2020-08-31
CL2020001277A1 (es) 2020-11-13
JOP20200127A1 (ar) 2020-05-21
EP3713927A1 (en) 2020-09-30
CU20200035A7 (es) 2021-03-11
IL274722A (en) 2020-07-30
RU2020120538A (ru) 2021-12-24
RU2020120538A3 (es) 2021-12-24
CN111433195A (zh) 2020-07-17
JP2021512850A (ja) 2021-05-20
EA202091293A1 (ru) 2020-11-23
CA3081651A1 (en) 2019-05-31
KR20200091422A (ko) 2020-07-30
CN111433195B (zh) 2023-04-25
AU2017440306A1 (en) 2020-05-21
PH12020550763A1 (en) 2021-04-26
CO2020005885A2 (es) 2020-07-31
EP3713927B1 (en) 2021-12-15
ECSP20026023A (es) 2020-07-31
AU2017440306B2 (en) 2021-01-28
BR112020010171A2 (pt) 2020-11-03
CR20200211A (es) 2020-06-19

Similar Documents

Publication Publication Date Title
PE20190761A1 (es) Inhibidores de procesos metabolicos celulares
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
AR102094A1 (es) Inhibidores de proteínas kras con una mutación g12c
PE20160044A1 (es) Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
AR056511A1 (es) Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4
PE20150339A1 (es) Carboxamidas heterociclicas fungicidas
AR078201A1 (es) Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos
PE20180457A1 (es) Piridinas sustituidas y metodo de uso
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
AR051795A1 (es) Derivados de hidantoina inhibidores de metaloproteinasas
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
AR084144A1 (es) Compuestos y metodos para restaurar la piel
EA201700504A1 (ru) 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение
AR051796A1 (es) Derivados de hidantoina como inhibidores de metaloproteinasas
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
EA201990343A1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2
CO2020012353A2 (es) Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos
EA201692300A1 (ru) Производные карбоксамида
PE20171335A1 (es) Inhibidores de gingipaina de lisina
EA201692298A1 (ru) Производные карбоксамидов